COVID-19: Bharat Biotech in preparation for booster dose, seeks approval for third clinical trial of its nasal vaccine

New Delhi, 20/12: Bharat Biotech has sent an application to DCGI for Phase III clinical trial of booster dose of Intranasal Covid Vaccine given through the nose. News agency ANI gave this information on Monday quoting its sources. The most important thing about this vaccine is that it can be given to all those people who have got either vaccine from Covaxin and Covishield.


Krishna Ella, Chairman and Managing Director of Bharat Biotech, emphasized the importance of the nasal vaccine at an event held in New Delhi on November 10. Along with this, he said in relation to the booster dose that the third dose should be given only six months after the second dose of the anti-Kovid-19 vaccine, this is the most appropriate time.

How important is the ‘Nasal Vaccine’?

Regarding the importance of ‘Nasal Vaccine’, he had said that the whole world wants such vaccines. He had said, “This is the only way to stop the infection. Everyone is trying to figure out ‘immunology’ and luckily, Bharat Biotech has figured it out.”

Comments are closed.